Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Akt inhibitors reduce glucose uptake independently of their effects on Akt

(2010) Shi-Xiong Tan et al.   BIOCHEMICAL JOURNAL

Medical comorbidities predict mortality in women with a history of early stage breast cancer

(2010) Ruth E. Patterson et al.   BREAST CANCER RESEARCH AND TREATMENT

Insulin-Mediated Acceleration of Breast Cancer Development and Progression in a Nonobese Model of Type 2 Diabetes

(2010) R. Novosyadlyy et al.   CANCER RESEARCH

Specific Roles of the p110α Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation

(2010) Victoria Rotter Sopasakis et al.   Cell Metabolism

Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes

(2010) Yvonne Fierz et al.   ENDOCRINE-RELATED CANCER

Elevated Circulating IGF-I Promotes Mammary Gland Development and Proliferation

(2010) Dara Cannata et al.   ENDOCRINOLOGY

Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis

(2010) Kimberly S. Peairs et al.   JOURNAL OF CLINICAL ONCOLOGY

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

(2010) N. A. O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

Activity of any class IA PI3K isoform can sustain cell proliferation and survival

(2010) L. C. Foukas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

(2009) Elena López-Knowles et al.   INTERNATIONAL JOURNAL OF CANCER

Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case–control study

(2009) C. Agnoli et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH